I'm really just going on history of BIO's here.
And sorry guys, but I'm not cross promoting. Completely different drugs.
But NEU completed a Ph2 in December last year. Not interim. Completed.
And the Ph3 end points have still not been agreed to. And yes they've met with the FDA.
I think that was in august. Too lazy to check
But from what I've seen is that you cant rush through FDA applications and you absolutely need someone who knows what they are doing when approaching the FDA.
Neuren did NOT do the work with the FDA for the Ph3 trial of trofentide (which eventually passed and was commercialised), they had a partner who knew the FDA.
Again, I like the stock.
But you cant run a theory of everything being condensed and flying through.
It's just so rare.
(20min delay)